Cargando…

Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria

BACKGROUND: Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings. We investigated the occurrence of these events in the national cohort of multidrug-resistant tubercu...

Descripción completa

Detalles Bibliográficos
Autores principales: Avong, Yohanna Kamabi, Isaakidis, Petros, Hinderaker, Sven Gudmund, Van den Bergh, Rafael, Ali, Engy, Obembe, Bolajoko Oladunni, Ekong, Ernest, Adebamowo, Clement, Ndembi, Nicaise, Okuma, James, Osakwe, Adeline, Oladimeji, Olanrewaju, Akang, Gabriel, Obasanya, Joshua Olusegun, Eltayeb, Osman, Agbaje, Aderonke Vivian, Abimiku, Alash’le, Mensah, Charles Olalekan, Dakum, Patrick Sunday
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364363/
https://www.ncbi.nlm.nih.gov/pubmed/25781958
http://dx.doi.org/10.1371/journal.pone.0120161
_version_ 1782362060791742464
author Avong, Yohanna Kamabi
Isaakidis, Petros
Hinderaker, Sven Gudmund
Van den Bergh, Rafael
Ali, Engy
Obembe, Bolajoko Oladunni
Ekong, Ernest
Adebamowo, Clement
Ndembi, Nicaise
Okuma, James
Osakwe, Adeline
Oladimeji, Olanrewaju
Akang, Gabriel
Obasanya, Joshua Olusegun
Eltayeb, Osman
Agbaje, Aderonke Vivian
Abimiku, Alash’le
Mensah, Charles Olalekan
Dakum, Patrick Sunday
author_facet Avong, Yohanna Kamabi
Isaakidis, Petros
Hinderaker, Sven Gudmund
Van den Bergh, Rafael
Ali, Engy
Obembe, Bolajoko Oladunni
Ekong, Ernest
Adebamowo, Clement
Ndembi, Nicaise
Okuma, James
Osakwe, Adeline
Oladimeji, Olanrewaju
Akang, Gabriel
Obasanya, Joshua Olusegun
Eltayeb, Osman
Agbaje, Aderonke Vivian
Abimiku, Alash’le
Mensah, Charles Olalekan
Dakum, Patrick Sunday
author_sort Avong, Yohanna Kamabi
collection PubMed
description BACKGROUND: Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings. We investigated the occurrence of these events in the national cohort of multidrug-resistant tuberculosis (MDR-TB) patients in Nigeria. METHOD: This was a retrospective, observational cohort study, using pharmacovigilance data systematically collected at all MDR-TB treatment centers in Nigeria. Characteristics of AEs during the intensive phase treatment were documented, and risk factors for development of AEs were assessed. RESULTS: Four hundred and sixty patients were included in the analysis: 62% were male; median age was 33 years [Interquartile Range (IQR):28–42] and median weight was 51 kg (IQR: 45–59). Two hundred and three (44%) patients experienced AEs; four died of conditions associated with SLD AEs. Gastro-intestinal (n = 100), neurological (n = 75), ototoxic (n = 72) and psychiatric (n = 60) AEs were the most commonly reported, whereas ototoxic and psychiatric AEs were the most debilitating. Majority of AEs developed after 1–2 months of therapy, and resolved in less than a month after treatment. Some treatment centers were twice as likely to report AEs compared with others, highlighting significant inconsistencies in reporting at different treatment centers. Patients with a higher body weight had an increased risk of experiencing AEs. No differences were observed in risk of AEs between HIV-infected and uninfected patients. Similarly, age was not significantly associated with AEs. CONCLUSION: Patients in the Nigerian MDR-TB cohort experienced a wide range of AEs, some of which were disabling and fatal. Early identification and prompt management as well as standardized reporting of AEs at all levels of healthcare, including the community is urgently needed. Safer regimens for drug-resistant TB with the shortest duration are advocated.
format Online
Article
Text
id pubmed-4364363
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43643632015-03-23 Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria Avong, Yohanna Kamabi Isaakidis, Petros Hinderaker, Sven Gudmund Van den Bergh, Rafael Ali, Engy Obembe, Bolajoko Oladunni Ekong, Ernest Adebamowo, Clement Ndembi, Nicaise Okuma, James Osakwe, Adeline Oladimeji, Olanrewaju Akang, Gabriel Obasanya, Joshua Olusegun Eltayeb, Osman Agbaje, Aderonke Vivian Abimiku, Alash’le Mensah, Charles Olalekan Dakum, Patrick Sunday PLoS One Research Article BACKGROUND: Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings. We investigated the occurrence of these events in the national cohort of multidrug-resistant tuberculosis (MDR-TB) patients in Nigeria. METHOD: This was a retrospective, observational cohort study, using pharmacovigilance data systematically collected at all MDR-TB treatment centers in Nigeria. Characteristics of AEs during the intensive phase treatment were documented, and risk factors for development of AEs were assessed. RESULTS: Four hundred and sixty patients were included in the analysis: 62% were male; median age was 33 years [Interquartile Range (IQR):28–42] and median weight was 51 kg (IQR: 45–59). Two hundred and three (44%) patients experienced AEs; four died of conditions associated with SLD AEs. Gastro-intestinal (n = 100), neurological (n = 75), ototoxic (n = 72) and psychiatric (n = 60) AEs were the most commonly reported, whereas ototoxic and psychiatric AEs were the most debilitating. Majority of AEs developed after 1–2 months of therapy, and resolved in less than a month after treatment. Some treatment centers were twice as likely to report AEs compared with others, highlighting significant inconsistencies in reporting at different treatment centers. Patients with a higher body weight had an increased risk of experiencing AEs. No differences were observed in risk of AEs between HIV-infected and uninfected patients. Similarly, age was not significantly associated with AEs. CONCLUSION: Patients in the Nigerian MDR-TB cohort experienced a wide range of AEs, some of which were disabling and fatal. Early identification and prompt management as well as standardized reporting of AEs at all levels of healthcare, including the community is urgently needed. Safer regimens for drug-resistant TB with the shortest duration are advocated. Public Library of Science 2015-03-17 /pmc/articles/PMC4364363/ /pubmed/25781958 http://dx.doi.org/10.1371/journal.pone.0120161 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Avong, Yohanna Kamabi
Isaakidis, Petros
Hinderaker, Sven Gudmund
Van den Bergh, Rafael
Ali, Engy
Obembe, Bolajoko Oladunni
Ekong, Ernest
Adebamowo, Clement
Ndembi, Nicaise
Okuma, James
Osakwe, Adeline
Oladimeji, Olanrewaju
Akang, Gabriel
Obasanya, Joshua Olusegun
Eltayeb, Osman
Agbaje, Aderonke Vivian
Abimiku, Alash’le
Mensah, Charles Olalekan
Dakum, Patrick Sunday
Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria
title Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria
title_full Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria
title_fullStr Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria
title_full_unstemmed Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria
title_short Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria
title_sort doing no harm? adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in nigeria
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364363/
https://www.ncbi.nlm.nih.gov/pubmed/25781958
http://dx.doi.org/10.1371/journal.pone.0120161
work_keys_str_mv AT avongyohannakamabi doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT isaakidispetros doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT hinderakersvengudmund doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT vandenberghrafael doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT aliengy doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT obembebolajokooladunni doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT ekongernest doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT adebamowoclement doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT ndembinicaise doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT okumajames doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT osakweadeline doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT oladimejiolanrewaju doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT akanggabriel doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT obasanyajoshuaolusegun doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT eltayebosman doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT agbajeaderonkevivian doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT abimikualashle doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT mensahcharlesolalekan doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria
AT dakumpatricksunday doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria